Page 6 - SLIDES
P. 6

CABOPRE: cabozantinib prior to cytoreductive nephrectomy










                                                  18                                                                       12wk ORR: 26.7%



                                     cabozantinib                                                                          12wk PR:                                   26.7%


                                             60mg x12wk





                  11 cytoreductive nephrectomy




                         1º outcome: ORR @12wk                                                                             Med PFS:                                   12.7m



                                                                                                                           12m OS:                                    70%






                                                                                                                           Median follow up 9m







                                                                                              st
                               Cabozantinib is feasible as 1 line treatment for mRCC and

                                     may enable selection for cytoreductive nephrectomy
   1   2   3   4   5   6   7   8   9   10   11